Isolation of bioactive proteins from natural product extracts

我们的努力导致了几类生物活性蛋白的发现，以及关于其潜在活性的出版物。这项研究还为我们的发现带来了34项专利，这些专利来自不同的许可证持有者。最近特别感兴趣的论文是我们报告了griffithsin（GRFT）蛋白的配制产品的快速溶解插入物，其显示出对SHIV、HSV-2和HPV 18的体内活性; GRFT在水稻中与另外两种杀微生物剂候选物的表达导致了新的专利申请，以及一类称为Tyr-Lock肽的新的环状肽的发现也导致了新的专利。该项目成功的另一个证据是，不同版本的GRFT蛋白的两个I期临床试验现已成功完成，其中一个试验的结果已提交出版。我们继续与这两个团体合作，以帮助进一步发展基于GRFT的产品通过诊所。最后，另外两项QGRFT突变蛋白鼻用制剂用于抗SARS-CoV-2的I期临床试验也即将启动。

Our efforts have led to the discovery of several classes of bioactive proteins as well as publications on their potential activity. This research has also led to 34 patents overall and significant interest for our discoveries from different licensees. Recent papers of particular interest were our report of fast-dissolving inserts of a formulated product of the protein griffithsin (GRFT) which showed in vivo activity against SHIV, HSV-2 and HPV18; the expression of GRFT in rice with two other microbicide candidates which led to a new patent filing, and the discovery of a new class of cyclic peptides called Tyr-Lock peptides which also led to a new patent. Additional evidence for the success of this project is the fact that two Phase I clinical trials of different versions of the protein GRFT have now been successfully completed for one of which, the results have been submitted for publication. We continue our collaborations with both groups to help further progress GRFT-based products through the clinic. Finally, two additional Phase I clinical trials of nasal formulations of the QGRFT mutant protein for use against SARS-CoV-2 are also nearing initiation.